An interventional study of Tab-G in Arthritis and Fatigue, sponsored by University of Massachusetts, Amherst. Completed at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by University of Massachusetts, Amherst · Not applicable, Interventional, and Supportive care
The purpose of this project is to pilot test a long-term effect of Tab-G (tablet-based cognitive behavioral group education intervention). The investigators will evaluate the effect of Tab-G, relative to usual care group, on (a) daily steps, (b) fatigue level, (c) self-efficacy and (d) quality of life.
Tab-G participants will receive 4 weekly CBT-based group education focusing on shared goal setting and mutual reinforcement in a group with 5 members. The outcomes will be measured baseline, week 4 (intervention completion) and week 8 (follow-up). The investigators hypothesize that older adults receiving Tab-G will have greater improvements on outcomes compared to those receiving usual care at week 4, the intervention completion and at week 8 follow-up.
3,555 studies on the registry are indexed under Arthritis; 313 are open to participants now.
This study's enrollment of 40 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →University of Massachusetts, Amherst is the lead sponsor of 48 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tab-G participants will receive 4 weekly CBT(cognitive behavioral therapy)-based group learning sessions to encourage a simple walking activity through videoconferencing meetings in a group of 5 members. The educational materials emphasize shared goal setting and mutual reinforcement.
Behavioral: Tab-G
A usual care group will receive general arthritis management education. Participant are instructed to maintain usual activity during the study period.
Participants receive a tablet preloaded with Tab-G application and an accelerometer.
Also known as: tablet-based group CBT education
daily steps
daily step counts measured by an accelerometer
Time frame: 24 hours
BRICS NINR PROMIS Fatigue Short Form 6a
self-reported fatigue scale measuring both the experience of fatigue and the interference of fatigue on daily activities. Scores can range from 6 to 30, with higher scores indicating greater fatigue.
Time frame: past 1 week
Self-Efficacy for Managing Chronic Disease 6-Item Scale
self-reported self-efficacy scale. Scores can range from 6 to 60, with higher scores indicating higher self-efficacy.
Time frame: 24 hours
Quality of Life-Rheumatoid Arthritis Scale
self-reported perception of quality of life. Scores can range from 8 to 80 with higher scores indicating greater quality of life.
Time frame: past 4 weeks
Ran from Jan 2021 to primary completion in Apr 2023, 27 months.
Of 352 non-industry interventional studies with no phase under Arthritis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's 27 months is close to that.
Counting every sponsor, half of 399 studies reached it within 26 months; a quarter within 11 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Massachusetts, Amherst